PL442046A1 - (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę - Google Patents

(E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę

Info

Publication number
PL442046A1
PL442046A1 PL442046A PL44204622A PL442046A1 PL 442046 A1 PL442046 A1 PL 442046A1 PL 442046 A PL442046 A PL 442046A PL 44204622 A PL44204622 A PL 44204622A PL 442046 A1 PL442046 A1 PL 442046A1
Authority
PL
Poland
Prior art keywords
melanogenesis
aminobutan
cinnamoylaminoalkanols
compound
inhibiting activity
Prior art date
Application number
PL442046A
Other languages
English (en)
Inventor
Agnieszka Gunia-Krzyżak
Justyna Popiół
Karolina Słoczyńska
Dorota Żelaszczyk
Katarzyna Wójcik-Pszczoła
Paulina KOCZURKIEWICZ-ADAMCZYK
Elżbieta Pękala
Henryk Marona
Magdalena Borczuch-Kostańska
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL442046A priority Critical patent/PL442046A1/pl
Priority to EP23461638.1A priority patent/EP4324461A1/en
Publication of PL442046A1 publication Critical patent/PL442046A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest związek o wzorze 1 korzystnie o konfiguracji E podwójnego wiązania, gdzie: R1 oznacza aminoalkanol, korzystnie: 6-aminoheksan-1-ol, 5-aminopentan-1-0l, 4-aminobutan-1-ol, 3-aminopropan-1-ol, 2-aminoetan-1-ol, (R,S)-2-aminopropan-1-ol, (R,S)-2-aminobutan-1-ol, (R,S)-1-aminobutan-2-ol, (R,S)-2-amino-3-metylobutan-1-ol lub 4-hydroksypiperydynę, R2 oznacza atom wodoru, atom chloru, dwa atomy chloru lub grupę metylową, w odpowiedniej pozycji pierścienia fenylowego, korzystnie 4 lub 2, 4, do stosowania w leczeniu lub zapobieganiu chorób lub zaburzeń związanych z nieprawidłową melanogenezą, przy czym związek ten jest stosowany do hamowania melanogenezy lub jako inhibitor tyrozynazy.
PL442046A 2022-08-19 2022-08-19 (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę PL442046A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL442046A PL442046A1 (pl) 2022-08-19 2022-08-19 (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę
EP23461638.1A EP4324461A1 (en) 2022-08-19 2023-08-19 (e)-n-cinamoylaminoalkanoles with melanogenesis inhibitory activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442046A PL442046A1 (pl) 2022-08-19 2022-08-19 (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę

Publications (1)

Publication Number Publication Date
PL442046A1 true PL442046A1 (pl) 2024-02-26

Family

ID=88287432

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442046A PL442046A1 (pl) 2022-08-19 2022-08-19 (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę

Country Status (2)

Country Link
EP (1) EP4324461A1 (pl)
PL (1) PL442046A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321754A (ja) * 1993-05-10 1994-11-22 Kao Corp 美白剤
KR20130035618A (ko) * 2011-09-30 2013-04-09 충남대학교산학협력단 신나모일살리실아미드 유도체를 유효성분으로 함유하는 미백용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096265A1 (en) * 1999-06-25 2003-05-22 Motorola, Inc. Phosphoramidites for coupling oligonucleotides to [2 + 2] photoreactive groups
WO2004084854A1 (en) 2003-03-25 2004-10-07 L'oreal Cosmetic use of cinnamic acid derivatives as lightening agents
GB0721332D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321754A (ja) * 1993-05-10 1994-11-22 Kao Corp 美白剤
KR20130035618A (ko) * 2011-09-30 2013-04-09 충남대학교산학협력단 신나모일살리실아미드 유도체를 유효성분으로 함유하는 미백용 조성물

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUNIA-KRZYŻAK A. I IN.,: "Bioorganic & Medicinal Chemistry, 15.01.2017, 25 (2), 471-482", "STRUCTURE-ANTICONVULSANT ACTIVITY STUDIES IN THE GROUP OF (E)-N-CINNAMOYL AMINOALKANOLS DERIVATIVES MONOSUBSTITUTED IN PHENYL RING WITH 4-CL, 4-CH3 OR 2-CH3", *
OKOMBI S. I IN.,: "Bioorganic & Medicinal Chemistry Letters, 15.04.2006;16(8):2252-5. doi: 10.1016/j.bmcl.2006.01.022", "ANALOGUES OF N-HYDROXYCINNAMOYLPHENALKYLAMIDES AS INHIBITORS OF HUMAN MELANOCYTE-TYROSINASE", *
ULLACH S. I IN.,: "Bioorg Chem. 2019 Jun;87:43-55. doi: 10.1016/j.bioorg.2019.03.001.", "TYROSINASE INHIBITION AND ANTI-MELANIN GENERATION EFFECT OF CINNAMAMIDE ANALOGUES", *
ULLACH S. I IN.,: "European journal of medicinal chemistry. 01.01.2019;161:78-92. doi: 10.1016/j.ejmech.2018.10.025", "SYNTHESIS OF CINNAMIC AMIDE DERIVATIVES AND THEIR ANTI-MELANOGENIC EFFECT IN Α-MSH-STIMULATED B16F10 MELANOMA CELLS",. *
WANG D. I IN.,: "Bioorganic & Medicinal Chemistry, 21.05.2019; 27(20):114918. doi: 10.1016/j.bmc.2019.05.031", "SYNTHESIS OF N-HYDROXYCINNAMOYL AMIDE DERIVATIVES AND EVALUATION OF THEIR ANTI-OXIDATIVE AND ANTI-TYROSINASE ACTIVITIES", *
ZAMAN A. I IN.: "Acta Crystallographica. Section C Structural Chemistry, 13.01.2016, 72(2), doi: 10.1107/S205322961502433X.", "SYNTHESIS AND CRYSTAL STRUCTURES OF THE POTENTIAL TYROSINASE INHIBITORS N -(4-ACETYLPHENYL)-2-CHLOROACETAMIDE AND 2-(4-ACETYLANILINO)-2-OXOETHYL CINNAMATE." *

Also Published As

Publication number Publication date
EP4324461A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
MX2024003960A (es) Compuestos antivirales que contienen nitrilo.
JOP20250246A1 (ar) مثبطات kras
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MY142807A (en) Benzimidazole derivative and use thereof.
BRPI0414680A (pt) oxadiazolidinadionas substituìdas como inibidores de pai-1
BR0014075A (pt) Inibidores de quinase como agentes terapêuticos
BG105596A (en) Substituted benzimidazoles and their use as parp inhibitors
TW200621786A (en) Condensed pyrazole derivatives, their preparation and application in therapeutics
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
ZA200600343B (en) Substituted 2-aminotetralin for the treatment of depression
MX2025010357A (es) Degradador de irak4, y uso del mismo
BR112023024311A2 (pt) Derivado de fenil ureia
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
JOP20240059A1 (ar) المركبات المثبطة إيميدازوبيريدازين il-17
FR2942625B1 (fr) Derives indoliques pour le traitement de maladies neurodegeneratives
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
MX2022015679A (es) Inhibidor de tyk-2.
PL442046A1 (pl) (E)-N-cynamoiloaminoalkanole o aktywności hamującej melanogenezę
BR0317740A (pt) Derivados de prostaglandinas para o tratamento de desconforto abdominal
ATE324108T1 (de) Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
MX2009006094A (es) Uso de derivados canfolenicos como ingredientes fragantes en perfumeria y saborizacion.
EA200970616A1 (ru) Соединения имидазолидинониламинопиримидина
MY207151A (en) Peptide amide composition and preparation method therefor
PL433567A1 (pl) Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych